Abstract
We read with great interest the study investigating the association between immunosuppressant and the outcome of patients withs SARS-CoV-2 infection [1]. They found that the prior use of immunosuppressant would be associated with a significantly increased risk of death (adjusted relative risk [RR], 1.56; 95% CI, 1.10–2.22) which was mainly driven by exposure to systemic glucocorticoids (aRR, 2.38; 95% CI 1.72–3.30). Overall, it is a well-designed study; however, we have three concerns about the findings of this study.